Atherosclerosis and Lipoproteins |
From the Research Laboratory for Infectious Diseases (A.M., A.v.d.V., J.M.O.) and the Laboratory for Pathology and Immunobiology (P.J.M.R., S.K.G.-P.), National Institute of Public Health and the Environment, Bilthoven; and the Department of Surgery, St. Radboud University Hospital (J.A.v.d.V.), Nijmegen, The Netherlands.
| Abstract |
|---|
|
|
|---|
Key Words: Chlamydia pneumoniae herpes simplex virus cytomegalovirus abdominal aortic aneurysms atherosclerosis
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
In Situ Detection of C pneumoniae, CMV, and
HSV
Adjacent to the hematoxylin-eosinstained sections, 4-µm
sections were used for detection of antigens by ICC through the use of
an indirect immunoperoxidase method. For detection of C
pneumoniae, 2 C pneumoniaespecific antimembrane
protein monoclonal antibodies, RR-40216 and
TT-40116 (Washington Research Foundation [WRF],
Seattle); 4 Chlamydia genusspecific
anti-lipopolysaccharide (LPS) monoclonal antibodies, 3 (16.3B6,
16.1D10, and 2.5F10) produced and characterized in our laboratory as
previously described17 and CF-218 (WRF);
and 1 Chlamydia genusspecific antiheat shock protein 60
(hsp60) monoclonal antibody (A57-B919 ; Affinity
Bioreagents Inc, SanverTECH, Breda, The Netherlands) were used. For
identification of macrophages, the anti-CD68 monoclonal
antibody PG-M1 (DAKO A/S, ITK Diagnostics BV, Uithoorn, The
Netherlands) was used. Toluidine blue (Sigma-Aldrich Chemie)
was used for staining of mast cells. Irrelevant primary monoclonal
antibodies of the same isotype were used as negative controls.
Peroxidase-labeled goat anti-mouse, anti-isotype antibodies (Southern
Biotechnology Associates, Inc, ITK Diagnostics, Uithoorn,
The Netherlands) were used as secondary antibodies. Before detection of
CMV, the sections were treated with trypsin. Then they were
successively incubated with a monoclonal antibody reactive with CMV
early antigen (Dako A/S, code CCH2), peroxidase-labeled rabbit
anti-mouse antibodies (Dako A/S), and peroxidase-labeled swine
anti-rabbit antibodies (Dako A/S) according to the instructions of the
manufacturer. For detection of HSV, a polyclonal rabbit antiserum
raised against an HSV-1 extract and reactive with type-specific as well
as type-common HSV antigens (Dako A/S, code B0114) followed by
peroxidase-labeled swine anti-rabbit antibodies (Dako A/S) was used.
For ICC with the 16.3B6 anti-LPS monoclonal antibody and for ICC
detection of CMV or HSV, tyramide signal amplification (NEN Life
Sciences Products) was used according to the instructions of the
manufacturer. Peroxidase was visualized with a diaminobenzidine/nickel
substrate (Sigma). The sections were counterstained with nuclear fast
red (Sigma).
Detection of C pneumoniae DNA by ISH in 4-µm sections adjacent to those used for ICC was carried out with a digoxigenin (DIG)-labeled C pneumoniae major outer membrane protein (MOMP) gene fragment (426 bp, from nucleotide 354 to nucleotide 779 of the MOMP gene; GenBank accession No. M69230) as a probe. A DIG-labeled minute virus of mouse genome fragment (202 bp, from nucleotide 586 to nucleotide 787; GenBank accession No. J02275) was used as a negative control probe. Both probes were labeled by PCR with DIG-labeled dUTP (Boehringer Mannheim) according to the instructions of the manufacturer. After the sections were dewaxed, they were digested for 15 minutes at 37°C with 5 mg/L proteinase K (Sigma) in 0.1 mol/L Tris-HCl (pH 7.6) containing 2 mmol/L CaCl2; washed twice with PBS for 5 minutes, once with 0.01% Triton X-100 in PBS for 10 minutes, and twice with PBS for 5 minutes; dehydrated; and dried. Hybridization mix (42% deionized formamide, 9.4% dextran sulfate, 5.8x salinesodium citrate buffer [SSC; 1x SSC is 15 mmol/L Na3H5C6O6 containing 150 mmol/L NaCl], 4.7x Denhardts solution [50x Denhardts solution is 1% BSA, 1% Ficoll, and 1% polyvinylpyrrolidone in water; Sigma], 94 mg/L denatured herring sperm DNA, and 50 µg/L probe) was heated for 10 minutes at 100°C, cooled on ice, and added to the sections. The slides were incubated for 5 minutes at 95°C to denature the DNA in the sections, immediately cooled on ice, and incubated overnight at 45°C. After being washed at 65°C, twice with 2x SSC for 15 minutes, once with 1x SSC for 5 minutes, and once with 0.5x SSC for 5 minutes, the hybridized probes were visualized with alkaline phosphataselabeled antiDIG Fab fragments (Boehringer Mannheim) and nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate substrate incubation overnight. The sections were counterstained with nuclear fast red (Sigma).
Sections of HEp2 cells (code CCL23; American Type Culture Collection [ATCC], Manassas, Va) infected with C pneumoniae strain TW-183 (WRF) at a multiplicity of infection of 0.1 inclusion-forming units (IFU) and of mock-infected HEp2 cells, fixed and embedded in paraffin similar to the clinical specimens, were used as positive and negative controls, respectively, for in situ detection of C pneumoniae. Paraffin sections of lung tissue infected with CMV or HSV (Dako A/S) were used as positive controls for in situ detection of CMV or HSV, respectively.
Clinical specimens were considered positive for C pneumoniae by ICC or ISH when a definite cell-associated cytoplasmic staining was observed and for CMV and HSV when definite staining within the nucleus and/or cytoplasm was observed. Specimens were scored positive when at least 1 clearly positive cell was observed.
PCR Assays for Detection of C pneumoniae, CMV,
and HSV
DNA isolation and PCR assays were performed as described
previously.20 DNA was isolated from finely minced vessel
wall tissue by using the Easy-DNA kit (Invitrogen BV) with additional
silica purification of the DNA. Five microliters of the specimen was
added to 20 µL of PCR mixture including the
dUTP-uracil N-glycosylase contamination prevention
system and anti-Taq polymerase antibodies. All possible
measures were taken to avoid false-positive results, in agreement with
recently published guidelines.21 For detection of
C pneumoniae, 1 primer set in the 16S rRNA gene and 1 in the
MOMP gene; for detection of CMV, 1 primer set in the immediate-early 1
gene and 1 in the glycoprotein B gene; and for detection of
HSV, 1 primer set in the immediate-early 2 gene and 1 in the
glycoprotein B gene were used.20 The
specificity of the amplicons was confirmed by Southern blotting and
hybridization with specific probes. Positive specimens were repeated in
the PCR assay with the same DNA preparation. A positive control (200 mg
of vessel wall tissue spiked with 100 IFUs of C pneumoniae
TW-183 and 100 50% tissue-culture infectious dose units of CMV strain
AD169 [ATCC VR-538], HSV-1 strain F [ATCC VR-733], and HSV-2 strain
G [ATCC VR-734], respectively) and negative controls (empty tubes),
one after the specimens of each patient, were included in each DNA
isolation. Negative PCR controls consisting of 5 µL of Tris-EDTA
buffer (10 mmol/L Tris-HCl [pH 7.5] containing 1 mmol/L
Na2EDTA) were included after every fifth specimen
in the PCR assay. All DNA preparations were checked for
inhibitors by adding DNA equivalent to 1 IFU of C
pneumoniae TW-183 directly to each PCR. A PCR assay amplifying a
536-bp fragment of the human ß-globin gene22 and
gel electrophoresis of the isolated DNA were used to assess the
integrity of the DNA in a random sample of 8 DNA specimens.
Detection of Antibodies Against C pneumoniae, CMV,
and HSV
Serum IgG antibodies to C pneumoniae were determined
with an enzyme immunoassay (EIA) developed in-house, the RIVM (National
Institute of Public Health and the Environment) EIA. The RIVM EIA was
carried out as previously described for C
trachomatis,17 23 with minor
modifications.24 The RIVM EIA performed equally well
compared with the microimmunofluorescence assay for detection of
antibodies against C pneumoniae.24
Untreated and sodium periodatetreated antigens of C
pneumoniae TW-183 and control antigen of mock-infected HEp2 cells
were used. Patient sera were tested at a dilution of 1:1000. A
reference serum was included in each assay. Titers of the patient
specimens were calculated relative to this reference serum.
Serum IgG antibodies to CMV and HSV were determined with Enzygnost Anti CMV/IgG and Enzygnost Anti HSV/IgG test kits according to the instructions of the manufacturer (Behringwerke AG).
Statistical Analysis
The geometric mean titer was calculated by taking the
antilogarithm of the mean of the log titers. The difference between
geometric mean titers was tested by an unpaired Students t
test with the computer program Statistica for Windows, version 5.0
(StatSoft Inc). A P value <0.05 was considered
statistically significant. Ninety-five percent CIs were calculated for
percentages by using Geigy Scientific Tables25 and
for geometric mean titers by using Students t
distribution.
| Results |
|---|
|
|
|---|
Control readings of ICC and ISH on sections of these specimens incubated with the control antibody and control probe, respectively, were negative. Control sections of HEp2 cells infected with C pneumoniae TW-183 were positive on ICC, with similar signal intensity for the different antibodies, and were also positive on ISH. Control sections of lung tissue infected with CMV or HSV were positive on ICC with the anti-CMV or anti-HSV antibodies, respectively.
The results of the detection of chlamydial, CMV, and HSV antigens in
the AAA specimens are summarized in Table 1
. Staining for chlamydial
antigens was predominantly found in pathological regions with an
inflammatory infiltrate and was observed in large
macrophage-like cells as a granular cytoplasmic staining
(Figure 1
). Cells stained for C
pneumoniaespecific membrane protein were found in the same area
as cells stained for the macrophage marker CD68 (Figure 2
) but not in the same area as
cells stained with toluidine blue, a marker for mast cells, in
adjacent sections. Although C pneumoniaespecific membrane
protein was detected in all patient specimens with the monoclonal
antibody RR-402, chlamydial LPS was less frequently positive (Figure 2
), and chlamydial hsp60 was detected in none of the specimens.
In general, the signal intensity and number of cells stained with the
monoclonal antibody TT-401 were less than with the monoclonal antibody
RR-402. In addition, usually a higher number of cells was stained more
intensely with the antiC pneumoniae membrane protein
antibodies than with the anti-chlamydial LPS antibodies (Figure 1
). The anti-LPS antibodies showed a patient-dependent
immunoreactivity, a summary of which is given in Figure 3
. Specimens from 4 patients were
completely negative, and specimens from only 3 patients were positive
with all 4 anti-LPS antibodies.
|
|
|
|
Staining of HSV antigens was found in the cytoplasm and nucleus of
lymphocytes in pathological regions with an inflammatory infiltrate in
specimens from 10 patients (Figure 2
), whereas the staining in 1
specimen could not be interpreted. Thus, 10 of 18 (56%; 95% CI 31%
to 78%) patients showed evidence of the coexistence of C
pneumoniae membrane protein and HSV antigens by ICC. However,
although both antigens were observed in the same region of the lesion,
they were found in different cell types.
The DNA specimens of 1 patient (No. 9) were lost during DNA isolation.
In a random sample of 8 DNA specimens, the size of the isolated DNA was
30 to 40 kbp, and a 536-bp ß-globin fragment could be amplified by
PCR from all of these specimens. Positive controls of spiked tissue and
negative controls of the DNA isolation and the PCR assays reacted
appropriately. No PCR inhibitors were detected in any of
the DNA specimens. The results of the detection of C
pneumoniae, CMV, and HSV DNAs by PCR in these specimens are
summarized in Table 2
. In total, from 4
patients 1 specimen was positive, 3 in the C pneumoniae 16S
rDNA PCR assay and 1 in the HSV immediate-early 2 gene PCR assay.
However, on retesting, these specimens were negative. They were also
negative in the C pneumoniae MOMP gene PCR assay and in the
HSV glycoprotein B gene PCR assay, respectively,
even after retesting. Furthermore, C
pneumoniaespecific MOMP gene DNA was not detected in any of the
paraffin-embedded AAA specimens of all patients by ISH.
|
Specific IgG antibodies to C pneumoniae were observed in sera from 15 of the 19 patients (79%; 95% CI 54% to 94%). The titers were between 1:800 and 1:12 800. Specimens from 2 of the 4 patients without IgG antibodies to C pneumoniae showed a high number and from the other 2 patients a moderate number of positive cells per section by ICC with monoclonal antibody RR-402. IgG antibodies to CMV were observed in sera from 15 of the 19 patients (79%; 95% CI 54% to 94%) and IgG antibodies to HSV in sera from 18 of the 19 patients (95%; 95% CI 74% to 100%). Specimens from the only patient without IgG antibodies to HSV showed a positive reaction on ICC. The geometric mean titer of IgG to HSV of the 10 ICC-positive and the 8 ICC-negative patients was not significantly different (reciprocal geometric mean titers of 3499 [95% CI 390 to 31 374] and of 11 527 [95% CI 5589 to 23 778], respectively; P=0.3).
| Discussion |
|---|
|
|
|---|
Specimens positive with the CF-2 antibody were confirmed by the RR-402 and TT-401 antibodies, in agreement with the results of Grayston and coworkers4 6 8 who used the same antibodies. In their strategy, the genus-specific antibody CF-2 either is used alone9 11 or for screening followed by confirmation with the species-specific antibody RR-402 or TT-401.4 6 8 However, only 32% (95% CI 13% to 57%; 6 of 19) of our specimens positive with the RR-402 antibody and only 31% (95% CI 11% to 59%; 5 of 16) of our specimens positive with the TT-401 antibody were positive with the CF-2 antibody. By using 3 additional anti-LPS antibodies, these percentages were raised to 79% (95% CI 54% to 94%; 15 of 19) and 75% (95% CI 48% to 93%; 12 of 16), respectively. All CF-2positive specimens were confirmed by at least 1 of the additional anti-LPS antibodies. The percentage of positive patients by ICC (19 of 19; 95% CI 82% to 100%) is in agreement with that reported by Juvonen et al14 for AAAs (12 of 12) by ICC. However, in contrast to our results, they detected chlamydial LPS in all patients and C pneumoniae protein in 8 of the 12 patients. An explanation might be the use of different monoclonal antibodies.
In this study, Chlamydia genusspecific anti-hsp60 antibodies were used to detect chlamydial hsp60 in atherosclerotic tissue. The absence of chlamydial hsp60 is not consistent with the assumption of persistent infection with Chlamydia.27 Although chlamydial hsp60 has been implicated in the pathogenesis of complications of chlamydial infections27 and induction of atherosclerosis in rabbits by the mycobacterial homologue of hsp60 has been demonstrated,28 our results do not support a major role for chlamydial hsp60 in advanced AAAs.
A possible explanation for the difference in detection of LPS and membrane protein antigen is a more rapid degradation of LPS than of membrane protein, resulting in the absence of all LPS epitopes in some patients. All anti-LPS monoclonal antibodies recognize oxidation-sensitive epitopes on the LPS molecule. The presence and colocalization with macrophages of myeloperoxidase in atherosclerotic lesions might explain the loss of oxidation-sensitive epitopes.29 Although these observations were based on studies of atherosclerotic lesions, chronic inflammation, as present in all our specimens, is the main cause of these oxidative reactions. Chronic inflammation is a hallmark of both atherosclerosis and aneurysm.30 31 However, because AAA is not as "pure" a model for the study of atherosclerosis31 32 as are plaques in other arteries, extrapolation should be done with caution. Sample error is a less likely explanation for the observed differences, because from all patients at least 3 specimens were taken from different locations in the aneurysmal vessel wall and the results were combined for each anti-LPS and anti-protein monoclonal antibody. Because all antibodies showed similar signal intensities on paraffin sections of cultured cells infected with C pneumoniae, differences in antibody avidity also cannot explain our results. In addition, because we clearly demonstrated the presence of chlamydial LPS and membrane protein, the most likely explanation for the absence of hsp60 is its rapid degradation after an infection with C pneumoniae. Alternatively, the presence of C pneumoniae remnants in macrophages may be explained by the "traveling" of macrophages, which have ingested and degraded bacteria at other sites in the body infected by C pneumoniae, to the inflammation process in the aortic wall, as suggested by Capron.33 Yet another possibility that may explain the difference in detection of C pneumoniae antigens is the involvement of other Chlamydia-like microorganisms. Recently, we detected new 16S rDNA sequences clustering together with the recently discovered Chlamydia-like organisms "Z"34 and "Parachlamydia acanthamoebae"35 by phylogenetic analysis.36 As the antigenic makeup of these new chlamydial microorganism has not been determined yet, cross-reactions of the currently used monoclonal antibodies with components of these new organisms cannot be excluded.
In contrast to many studies in which PCR assays have been used4 5 6 7 8 9 11 13 14 15 but in agreement with the reports of Weiss et al37 studying coronary atheromas, Lindholt et al38 studying AAAs, and Paterson et al39 studying carotid and coronary atheromas, the presence of C pneumoniae DNA could not be demonstrated. However, our PCR assay should be positive if we assume that the observed positivity for C pneumoniae antigens (frequently >10 cells per AAA section) is caused by intact Chlamydia particles. Previously, we demonstrated the reliability of our DNA isolation procedure and PCR assays to detect microbial DNA in vessel wall specimens.20 To exclude sample error, 4 to 9 specimens of 50 to 300 mg per patient were analyzed. Furthermore, our ISH results confirmed the absence of C pneumoniae DNA, in agreement with the findings of Ramirez et al.5 Therefore, we concluded that C pneumoniae DNA is not present or is heavily degraded after infection and that the positive immunoreactivity does not represent intact Chlamydia particles. In addition, in line with the molecular revision of Kochs postulates by Fredericks and Relman,40 we suggest that confirmation of the presence of C pneumoniae DNA in vessel walls should be obtained by in situ techniques showing the localization of DNA in the cells in which other components of C pneumoniae are also detected.
In agreement with previous reports,4 10 14 there was no correlation between the presence of antigen-positive cells in paraffin sections of vessel wall specimens and the presence or titer of serum IgG antibodies. In addition, Maass et al41 recently showed that serology with the use of the microimmunofluorescence assay is not a reliable parameter to predict individual vascular C pneumoniae infection.
HSV antigens were detected in specimens of 56% (95% CI 31% to 78%) of the patients by ICC, but HSV DNA could not be detected by PCR. CMV antigen was not detected by ICC, nor was CMV DNA by PCR. These results are in agreement with those from Raza-Ahmad et al42 in coronary arteries by ICC (HSV 48%) and Satta et al43 in AAAs by ICC and electron microscopy (CMV not detectable). However, our results were different from those of Chiu et al10 in carotid arteries by ICC (CMV 36% and HSV 11% positive) and Tanaka et al44 in AAAs by PCR (CMV 68% and HSV 27% positive).
In conclusion, detecting C pneumoniae in vessel wall specimens using only 1 technique might cause misinterpretations about the presence of C pneumoniae. Results of several techniques combined provide a better view of the actual situation at a certain point in time of a long and continuing disease process. The most likely explanation for our results is a difference in kinetics of degradation of chlamydial components after an infection, rather than persistence of viable Chlamydia. Our findings suggest a rapid degradation of hsp60 and DNA, followed by degradation of LPS, and the persistence of membrane proteins. How this process is influenced by the underlying disease remains to be investigated. Also, because atherosclerosis and aneurysm could be distinct diseases, extrapolation should be done with caution.
| Acknowledgments |
|---|
Received December 14, 1998; accepted March 24, 1999.
| References |
|---|
|
|
|---|
2. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Mäkelä PH, Huttunen JK, Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983986.[Medline] [Order article via Infotrieve]
3. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J. 1992;82:158161.[Medline] [Order article via Infotrieve]
4. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:841849.[Medline] [Order article via Infotrieve]
5.
Ramirez JA, the Chlamydia
pneumoniae/Atherosclerosis study group. Isolation
of Chlamydia pneumoniae from the coronary artery of
a patient with coronary atherosclerosis.
Ann Intern Med. 1996;125:979982.
6. Jackson LA, Campbell LA, Schmidt RA, Kuo CC, Cappuccio AL, Lee MJ, Grayston JT. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol.. 1997;150:17851790.[Abstract]
7.
Maass M, Bartels C, Engel PM, Mamat U, Sievers HH.
Endovascular presence of viable Chlamydia pneumoniae is a
common phenomenon in coronary artery disease. J Am
Coll Cardiol. 1998;31:827832.
8.
Grayston JT, Kuo CC, Coulson AS, Campbell LA, Lawrence
RD, Lee MJ, Strandness ED, Wang SP. Chlamydia pneumoniae
(TWAR) in atherosclerosis of the carotid artery.
Circulation. 1995;92:33973400.
9. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis. 1997;176:292295.[Medline] [Order article via Infotrieve]
10.
Chiu B, Viira E, Tucker W, Fong IW. Chlamydia
pneumoniae, cytomegalovirus, and herpes simplex virus in
atherosclerosis of the carotid artery.
Circulation. 1997;96:21442148.
11. Kuo CC, Coulson AS, Campbell LA, Cappuccio AL, Lawrence RD, Wang SP, Grayston JT. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg. 1997;26:2931.[Medline] [Order article via Infotrieve]
12.
Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of
Chlamydia pneumoniae in aortic lesions of
atherosclerosis by immunocytochemical stain.
Arterioscler Thromb. 1993;13:15011504.
13. Blasi F, Denti F, Erba M, Cosentini R, Raccanelli R, Rinaldi A, Fagetti L, Esposito G, Ruberti U, Allegra L. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol. 1996;34:27662769.[Abstract]
14. Juvonen J, Juvonen T, Laurila A, Alakärppä H, Lounatmaa K, Surcel HM, Leinonen M, Kairaluoma MI, Saikku P. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg. 1997;25:499505.[Medline] [Order article via Infotrieve]
15. Petersen E, Boman J, Persson K, Arnerlöv C, Wadell G, Juto P, Eriksson A, Dahlén G, Ängquist KA. Chlamydia pneumoniae in human abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 1998;15:138142.[Medline] [Order article via Infotrieve]
16. Puolakkainen M, Parker J, Kuo CC, Grayston JT, Campbell LA. Further characterization of Chlamydia pneumoniae specific monoclonal antibodies. Microbiol Immunol. 1995;39:551554.[Medline] [Order article via Infotrieve]
17. Ossewaarde JM, Manten JW, Hooft HJ, Hekker AC. An enzyme immunoassay to detect specific antibodies to protein and lipopolysaccharide antigens of Chlamydia trachomatis. J Immunol Methods.. 1989;123:293298.
18.
Swanson AF, Kuo CC. Evidence that the major outer
membrane protein of Chlamydia trachomatis is glycosylated.
Infect Immun. 1991;59:21202125.
19.
Yuan Y, Lyng K, Zhang YX, Rockey DD, Morrison RP.
Monoclonal antibodies define genus-specific, species-specific, and
cross-reactive epitopes of the chlamydial 60-kilodalton heat shock
protein (hsp60): specific immunodetection and purification of
chlamydial hsp60. Infect Immun. 1992;60:22882296.
20. Meijer A, Van der Vliet JA, Roholl PJM, Schouls LM, Ossewaarde JM. Detection of microorganisms in vessel wall specimens of the abdominal aorta: development of a PCR assay in the absence of a gold standard. Res Microbiol. 1998;149:577583.[Medline] [Order article via Infotrieve]
21.
Neumaier M, Braun A, Wagener C. Fundamentals of quality
assessment of molecular amplification methods in clinical
diagnostics. Clin Chem. 1998;44:1226.
22. Greer CE, Peterson SL, Kiviat NB, Manos MM. PCR amplification from paraffin-embedded tissues: effects of fixative and fixation time. Am J Clin Pathol. 1991;95:117124.[Medline] [Order article via Infotrieve]
23. Ossewaarde JM, De Vries A, Van den Hoek JAR, Van Loon AM. Enzyme immunoassay with enhanced specificity for detection of antibodies to Chlamydia trachomatis. J Clin Microbiol.. 1994;32:14191426.
24.
Ladany S, Black CM, Farshy CE, Ossewaarde JM, Barmes
RC. Enzyme immunoassay to determine exposure to Chlamydia
pneumoniae (strain TWAR). J Clin Microbiol. 1989;27:27782783.
25. Lentner C, ed. Geigy Scientific Tables. 8th rev ed. Basel, Switzerland: Ciba-Geigy Ltd; 1982.
26.
Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S,
Insull W, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A
definition of advanced types of atherosclerotic lesions and a
histological classification of
atherosclerosis. Arterioscler Thromb Vasc
Biol. 1995;15:15121531.
27. Ward ME The immunobiology and immunopathology of chlamydial infections. APMIS. 1995;103:769796.[Medline] [Order article via Infotrieve]
28. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:2733.[Medline] [Order article via Infotrieve]
29. Heinecke JW. Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine. Biofactors. 1997;6:145155.[Medline] [Order article via Infotrieve]
30.
Ross R. Atherosclerosis: an
inflammatory disease. N Engl J Med.. 1999;340:115126.
31. Shah PK. Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. Circulation. 1997;7:21152117.
32. Wills A, Thompson MM, Crowther M, Sayers RD, Bell PRF. Pathogenesis of abdominal aortic aneurysms: cellular and biochemical mechanisms. Eur J Vasc Endovasc Surg.. 1996;12:391400.[Medline] [Order article via Infotrieve]
33. Capron L. Chlamydia in coronary plaques: hidden culprit or harmless hobo? Nat Med. 1996;2:856857.[Medline] [Order article via Infotrieve]
34. Kahane S, Metzer E, Friedman MG. Evidence that the novel microorganism Z may belong to a new genus in the family, Chlamydiaceae. FEMS Microbiol Lett.. 1995;126:203208.[Medline] [Order article via Infotrieve]
35. Amann R, Springer N, Schönhuber W, Ludwig W, Schmid EN, Müller KD, Michel R. Obligate intracellular bacterial parasites of acanthamoebae related to Chlamydia spp. Appl Environ Microbiol. 1997;63:115121.[Abstract]
36. Ossewaarde JM, Meijer A. Molecular evidence for the existence of additional members of the order Chlamydiales. Microbiology.. 1999;145:411417.
37. Weiss SM, Roblin PM, Gaydos CA, Cummings P, Patton DL, Schulhoff N, Shani J, Frankel R, Penney K, Quinn TC, Hammerschlag MR, Schachter J. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis. 1996;173:957962.[Medline] [Order article via Infotrieve]
38. Lindholt JS, Østergård L, Henneberg EW, Fasting H, Andersen P. Failure to demonstrate Chlamydia pneumoniae in symptomatic abdominal aortic aneurysms by a nested polymerase chain reaction (PCR). Eur J Vasc Endovasc Surg. 1998;15:161164.[Medline] [Order article via Infotrieve]
39. Paterson DL, Hall J, Rasmussen SJ, Timms P. Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients. Pathology. 1998;30:169172.[Medline] [Order article via Infotrieve]
40. Fredericks DN, Relman DA. Sequence-based identification of microbial pathogens: a reconsideration of Kochs postulates. Clin Microbiol Rev. 1996;9:1833.[Abstract]
41. Maass M, Gieffers J, Krause E, Engel PM, Bartels C, Solbach W. Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients. Med Microbiol Immunol. 1998;187:103106.[Medline] [Order article via Infotrieve]
42. Raza-Ahmad A, Klassen GA, Murphy DA, Sullivan JA, Kinley CE, Landymore RW, Wood JR. Evidence of type 2 herpes simplex infection in human coronary arteries at the time of coronary artery bypass surgery. Can J Cardiol. 1995;11:10251029.[Medline] [Order article via Infotrieve]
43. Satta J, Laurila A, Paakko P, Haukipuro K, Sormunen R, Parkkila S, Juvonen T. Chronic inflammation and elastin degradation in abdominal aortic aneurysm disease: an immunohistochemical and electron microscopic study. Eur J Vasc Endovasc Surg. 1998;15:313319.[Medline] [Order article via Infotrieve]
44. Tanaka S, Komori K, Okadome K, Sugimachi K, Mori R. Detection of cytomegalovirus infection in inflammatory aortic aneurysms with RNA polymerase chain reaction. J Vasc Surg. 1994;20:235243.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
J. Golledge, J. Muller, A. Daugherty, and P. Norman Abdominal Aortic Aneurysm: Pathogenesis and Implications for Management Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2605 - 2613. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Meijer, P. J. M. Roholl, J. M. Ossewaarde, B. Jones, and B. F. Nowak Molecular Evidence for Association of Chlamydiales Bacteria with Epitheliocystis in Leafy Seadragon (Phycodurus eques), Silver Perch (Bidyanus bidyanus), and Barramundi (Lates calcarifer) Appl. Envir. Microbiol., January 1, 2006; 72(1): 284 - 290. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Duftner, R. Seiler, P. Klein-Weigel, H. Gobel, C. Goldberger, C. Ihling, G. Fraedrich, and M. Schirmer High Prevalence of Circulating CD4+CD28- T-Cells in Patients With Small Abdominal Aortic Aneurysms Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1347 - 1352. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. F. Berg, B. Maraha, A. van der Zee, S. K. Gielis, P. J. M. Roholl, G.-J. Scheffer, M. F. Peeters, and J. A. J. W. Kluytmans Effect of Clarithromycin Treatment on Chlamydia pneumoniae in Vascular Tissue of Patients with Coronary Artery Disease: a Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Microbiol., March 1, 2005; 43(3): 1325 - 1329. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Ieven and V. Y. Hoymans Involvement of Chlamydia pneumoniae in Atherosclerosis: More Evidence for Lack of Evidence J. Clin. Microbiol., January 1, 2005; 43(1): 19 - 24. [Full Text] [PDF] |
||||
![]() |
B. Maraha, H. Berg, M. Kerver, S. Kranendonk, J. Hamming, J. Kluytmans, M. Peeters, and A. van der Zee Is the Perceived Association between Chlamydia pneumoniae and Vascular Diseases Biased by Methodology? J. Clin. Microbiol., September 1, 2004; 42(9): 3937 - 3941. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Netea, B. J. Kullberg, L. E. H. Jacobs, T. J. G. Verver-Jansen, J. van der Ven-Jongekrijg, J. M. D. Galama, A. F. H. Stalenhoef, C. A. Dinarello, and J. W. M. Van der Meer Chlamydia pneumoniae Stimulates IFN-{gamma} Synthesis through MyD88-Dependent, TLR2- and TLR4-Independent Induction of IL-18 Release J. Immunol., July 15, 2004; 173(2): 1477 - 1482. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Y. Hoymans, J. M. Bosmans, D. Ursi, W. Martinet, F. L. Wuyts, E. Van Marck, M. Altwegg, C. J. Vrints, and M. M. Ieven Immunohistostaining Assays for Detection of Chlamydia pneumoniae in Atherosclerotic Arteries Indicate Cross-Reactions with Nonchlamydial Plaque Constituents J. Clin. Microbiol., July 1, 2004; 42(7): 3219 - 3224. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, Z. Pan, Y. Ji, M. Sheppard, D. J. Jeffries, L. C. Archard, and H. Zhang Herpes Simplex Virus Type 1 Infection Associated with Atrial Myxoma Am. J. Pathol., December 1, 2003; 163(6): 2407 - 2412. [Abstract] [Full Text] |
||||
![]() |
S Cagli, N Oktar, T Dalbasti, S Erensoy, N Ozdamar, S Goksel, A Sayiner, and A Bilgic Failure to detect Chlamydia pneumoniae DNA in cerebral aneursymal sac tissue with two different polymerase chain reaction methods J. Neurol. Neurosurg. Psychiatry, June 1, 2003; 74(6): 756 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Kalayoglu, P. Libby, and G. I. Byrne Chlamydia pneumoniae as an Emerging Risk Factor in Cardiovascular Disease JAMA, December 4, 2002; 288(21): 2724 - 2731. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Apfalter, O. Assadian, F. Blasi, J. Boman, C. A. Gaydos, M. Kundi, A. Makristathis, M. Nehr, M. L. Rotter, and A. M. Hirschl Reliability of Nested PCR for Detection of Chlamydia pneumoniae DNA in Atheromas: Results from a Multicenter Study Applying Standardized Protocols J. Clin. Microbiol., December 1, 2002; 40(12): 4428 - 4434. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vink, A. H. Schoneveld, J. J. van der Meer, B. J. van Middelaar, J. P.G. Sluijter, M. B. Smeets, P. H.A. Quax, S. K. Lim, C. Borst, G. Pasterkamp, et al. In Vivo Evidence for a Role of Toll-Like Receptor 4 in the Development of Intimal Lesions Circulation, October 8, 2002; 106(15): 1985 - 1990. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. M. Roholl, A. Herrewegh, D. van Soolingen, L. A. Sechi, M. Mura, S. Zanetti, F. Tanda, A. Lissia, and G. Fadda Positive IS900 In Situ Hybridization Signals as Evidence for Role of Mycobacterium avium subsp. paratuberculosis in Etiology of Crohn's Disease J. Clin. Microbiol., August 1, 2002; 40(8): 3112 - 3113. [Full Text] [PDF] |
||||
![]() |
M. VALASSINA, L. MIGLIORINI, A. SANSONI, G. SANI, D. CORSARO, M. G. CUSI, P. E. VALENSIN, and C. CELLESI Search for Chlamydia pneumoniae genes and their expression in atherosclerotic plaques of carotid arteries J. Med. Microbiol., March 1, 2001; 50(3): 228 - 232. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Apfalter, F. Blasi, J. Boman, C. A. Gaydos, M. Kundi, M. Maass, A. Makristathis, A. Meijer, R. Nadrchal, K. Persson, et al. Multicenter Comparison Trial of DNA Extraction Methods and PCR Assays for Detection of Chlamydia pneumoniae in Endarterectomy Specimens J. Clin. Microbiol., February 1, 2001; 39(2): 519 - 524. [Abstract] [Full Text] |
||||
![]() |
A Meijer, P J M Roholl, S K Gielis-Proper, Y F Meulenberg, and J M Ossewaarde Chlamydia pneumoniae in vitro and in vivo: a critical evaluation of in situ detection methods J. Clin. Pathol., December 1, 2000; 53(12): 904 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Meijer, P J M Roholl, S K Gielis-Proper, and J M Ossewaarde Chlamydia pneumoniae antigens, rather than viable bacteria, persist in atherosclerotic lesions J. Clin. Pathol., December 1, 2000; 53(12): 911 - 916. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |